Published in Clin J Am Soc Nephrol on October 25, 2016
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 3. Clin J Am Soc Nephrol (2016) 0.75
Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1. Clin J Am Soc Nephrol (2016) 0.75
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2. Clin J Am Soc Nephrol (2016) 0.75
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50
Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol (2014) 3.75
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (2001) 3.64
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94
The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol (2011) 2.61
Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation (2012) 2.56
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol (2014) 2.18
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol (2014) 1.59
Determinants of the response to oral anticoagulant drugs in man. Pharmacol Rev (1970) 1.56
Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J (2010) 1.55
Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol (2014) 1.55
Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest (2016) 1.52
Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol (2010) 1.51
Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.27
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis (2012) 1.05
Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med (2010) 1.01
Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol (2014) 0.92
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost (2015) 0.90
Relationships between Anticoagulation, Risk Scores and Adverse Outcomes in Dialysis Patients with Atrial Fibrillation. Heart Lung Circ (2015) 0.87
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol (2015) 0.85
Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis (2015) 0.85
Stroke prevention in patients with atrial fibrillation and renal dysfunction. Stroke (2014) 0.81
Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study. Int J Cardiol (2015) 0.80
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. Eur Heart J (2014) 0.78